Every Form 4 that Veradermics, Incorporated (MANE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MANE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MANE filings page.
Veradermics, Inc (MANE) reported that Chief R&D Officer David Hollander received equity awards on September 1, 2026. He was granted 9,650 shares of Common Stock in the form of restricted stock units and a stock option for 19,300 shares at an exercise price of $97.51 per share, both held directly.
The RSUs vest 25% on each of September 1, 2027, 2028, 2029, and 2030, subject to continued service. The option vests 25% on September 1, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months and expires on September 1, 2036.
Veradermics, Inc (MANE) had multiple entities associated with the reporting group, including Montanova Capital, LLC and Averill funds, report transactions in its securities. On 2026-08-20 they exercised 300,000 Pre-Funded Warrants into 300,000 shares of common stock, all reported as indirect ownership. On 2026-08-19 they reported indirect open-market or private sales of an aggregate 750,000 shares of common stock at a reported price of $107.25 per share. Resulting ownership balances are not provided in the data shown.
Veradermics, Inc (MANE) reported that its Chief Technical Officer, Timothy August Durso, exercised stock options for 3,452 shares of Common Stock at an exercise price of $12.19 per share and on the same date sold an aggregate of 43,500 Common shares in multiple open-market transactions at weighted average prices ranging from about $106.71 to $111.28 per share. The option was fully vested and exercisable, and the transactions were made pursuant to a Rule 10b5-1 trading plan.
Veradermics, Inc (MANE) reported insider activity by Chief Executive Officer Reid Alexander Waldman. On 2026-08-17 he exercised 3,452 stock options to acquire an equal number of common shares at an exercise price of $12.19 per share from a fully vested option. On the same date, he reported open-market sales totaling 67,500 common shares in multiple tranches at reported weighted-average prices between $106.07 and $111.28 per share, executed pursuant to a Rule 10b5-1 trading plan.
Entities associated with Veradermics, Inc director John W. Childs reported selling a total of 100,000 shares of Veradermics common stock on August 12, 2026. The shares were held indirectly through the John W. Childs 2013 Revocable Trust and J.W. Childs Associates (FL), L.P., with prices based on weighted-average sale ranges.
Veradermics, Inc. investment entities reported new derivative awards rather than open-market trades. On May 1, 2026, reporting persons including Suvretta Capital Management, LLC and Averill funds reported the indirect acquisition of two blocks of Pre-Funded Warrants for 151,000 and 149,000 underlying shares of Veradermics common stock. These transactions are coded as grants or awards, so they increase indirect exposure to Veradermics without reflecting discretionary buying or selling in the open market.
Veradermics, Inc director John W. Childs, through the John W. Childs 2013 Revocable Trust, indirectly bought 294,117 shares of Common Stock at $17.00 per share in an open‑market purchase. This amended Form 4 corrects the earlier report by clarifying that the shares are held via the revocable trust rather than J.W. Childs Associates (FL), L.P.
Veradermics, Inc. reported multiple insider share purchases by major holders linked to Suvretta Capital Management, LLC over several days in early February 2026. These indirect open‑market transactions involved common stock at prices in the mid‑$30s per share.
On February 4, 2026, reported indirect purchases included 53,344 shares of common stock at $37.11 per share, bringing one reported indirect position to 3,604,141 shares. Additional indirect buys continued on February 5 and 6, 2026, including 19,338 shares at $36.55 per share, after which one indirect holding stood at 520,453 shares.
Veradermics, Inc. director Katarina Pance received a grant of stock options for 43,000 shares of common stock on February 3, 2026. The options carry an exercise price of $17 per share and are held as a direct ownership position.
The award was reported as an acquisition under a grant or award transaction code. According to the terms, the option will become fully vested and exercisable on February 3, 2027, which is the first anniversary of the vesting commencement date.
Veradermics, Inc. director Jane M. Grant-Kels reported acquiring equity through an option grant and a preferred stock conversion. On February 3, 2026, she received a stock option for 51,525 shares of common stock at an exercise price of $17 per share, which will be fully vested and exercisable on February 3, 2027.
On February 5, 2026, 2,455 shares of Series A Convertible Preferred Stock automatically converted into 2,455 shares of common stock on a 10.067-for-1 basis, without additional payment, immediately before the closing of Veradermics’ initial public offering, leaving her with 2,455 common shares held directly.
Veradermics, Inc. reported that director David Matthew Friedman was granted a stock option covering 43,000 shares of common stock at an exercise price of $17 per share on February 3, 2026. The option is scheduled to become fully vested and exercisable on February 3, 2027.
According to the disclosure, Friedman, an employee of Suvretta Capital Management, LLC, is holding this award for the benefit of Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd. He disclaims beneficial ownership of the option, while the Funds and Suvretta Capital may be deemed to have an indirect pecuniary interest through rights to receive director compensation linked to his board service.
Veradermics, Inc. director Vladimir Coric reported multiple equity-acquiring transactions in connection with the company’s initial public offering. On February 5, 2026, Series A, B, and C convertible preferred shares automatically converted into common stock on a 10.067-for-1 basis immediately before the IPO closing.
These conversions resulted in common stock holdings shown at 33,706 shares from Series A, 148,794 from Series B, and additional common shares from Series C, split between direct ownership and entities referenced in the footnotes. Through the Vladimir Coric Family Trust 2013 and the Vladimir Coric Marital Trust 2013, indirect positions increased via these conversions.
On February 5, 2026, the trusts also executed an open-market purchase of 58,823 shares of common stock at $17 per share, bringing indicated indirect common stock holdings to 319,398 shares. Separately, on February 3, 2026, Coric received a stock option grant covering 51,525 shares at a $17 exercise price, which becomes fully vested and exercisable on February 3, 2027.
Veradermics, Inc. director John W. Childs reported multiple equity transactions tied to the company’s initial public offering. On February 5, 2026, entities associated with him converted Series A, B and C convertible preferred stock into Veradermics common shares on a 10.067-for-1 basis, resulting in 480,269, 906,862 and 520,758 common shares, respectively, all held indirectly through J.W. Childs Associates (FL), L.P. The same day, that entity also made an indirect open-market purchase of 294,117 common shares at $17 per share, bringing total indirect common stock holdings to 2,202,006 shares. Separately, on February 3, 2026, Childs received a direct stock option grant for 51,525 shares at a $17 exercise price, which becomes fully vested and exercisable on February 3, 2027.
Veradermics, Inc. reported insider activity by affiliated 10% owners on February 5, 2026. Investment funds Longitude Venture Partners V, L.P. and Longitude 103.8 East, L.P., through their general partner entities, converted existing Series B and Series C Convertible Preferred Stock into common stock in connection with Veradermics’ initial public offering, at a 10.067-for-1 conversion ratio without additional consideration.
The same affiliated entities also made indirect open-market or private purchases of Veradermics common stock at $17 per share, acquiring 192,647 shares in one account and 882,353 shares in another. Following these transactions, they reported multi-million-share indirect common stock holdings, while their managing entities and individuals disclaim beneficial ownership beyond their pecuniary interests.
Veradermics, Inc. director and 10% owner Patrick G. Enright reported indirect conversions and purchases of common stock. On February 5, 2026, Series B and Series C Convertible Preferred Stock automatically converted into 1,236,631 and 1,171,121 shares of common stock, respectively, on a 10.067-for-1 basis immediately before the closing of the company’s initial public offering, with no additional consideration.
Entities affiliated with Enright then bought 192,647 and 882,353 common shares at $17 per share, held through Longitude Venture Partners V, L.P. and Longitude 103.8 East, L.P., where voting and investment power is shared and beneficial ownership is disclaimed beyond pecuniary interests. On February 3, 2026, Enright also received a direct stock option for 45,131 shares at a $17 exercise price, vesting in full on February 3, 2027.
Veradermics, Inc. reported that its General Counsel, Michael V. Greco, received a grant of stock options on February 3, 2026. The award covers 144,401 stock options with an exercise price of $17 per share, held as direct beneficial ownership.
According to the vesting terms, 25% of the options vest on February 3, 2027, the first anniversary of the vesting commencement date. The remaining options vest in equal monthly installments over the following 36 months, contingent on continued service with the company.
Veradermics, Inc. reported that officer Mark Neumann, its Chief Commercial Officer and Strategy Officer, received a grant of stock options on February 3, 2026. The award covers 102,885 stock options with an exercise price of $17 per share.
According to the vesting terms, 25% of the underlying common shares vest on February 3, 2027, with the remaining options vesting in equal monthly installments over the following 36 months, subject to continued service. After this grant, Neumann directly holds 102,885 derivative securities.
Carrano Dominic Gabriel reported acquisition or exercise transactions in a Form 4 filing for MANE. The filing lists transactions totaling 148,011 shares. Following the reported transactions, holdings were 148,011 shares.
Veradermics, Inc. Chief Technical Officer Timothy August Durso reported stock-based transactions and updated his holdings. On February 3, 2026, he received a stock option grant for 213,352 shares of common stock at an exercise price of $17 per share. The option vests 25% on February 3, 2027, with the remaining shares vesting in equal monthly installments over 36 months, subject to continued service.
On February 5, 2026, 1,473 shares of Series A Convertible Preferred Stock automatically converted to 1,473 shares of common stock on a 10.067-for-1 basis without additional payment, immediately before the company’s initial public offering. After these transactions, Durso directly held 118,190 common shares and had an option over 213,352 shares, and 116,717 common shares were held indirectly by the Durso Family Trust. The trust is for the benefit of his children, is administered by his spouse as trustee, and Durso disclaims beneficial ownership of those trust-held shares.
Veradermics, Inc. Chief Executive Officer and director Reid Alexander Waldman reported insider equity changes. On February 5, 2026, 1,437 shares of Series A Convertible Preferred Stock automatically converted into 1,437 shares of common stock on a 10.067-for-1 basis, bringing his directly held common stock to 234,872 shares.
Separately, on February 3, 2026, he was granted a stock option for 556,399 shares of common stock at an exercise price of $17 per share. The option vests 25% on February 3, 2027, with the remainder vesting in equal monthly installments over the following 36 months, subject to continued service.